Sarah Cavanaugh - 17 Aug 2022 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP OF CORP AFFAIRS & ADMIN.
Signature
/s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh
Issuer symbol
CLDX
Transactions as of
17 Aug 2022
Net transactions value
-$1,100,246
Form type
4
Filing time
19 Aug 2022, 16:06:50 UTC
Previous filing
17 Jun 2022
Next filing
20 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $87,047 +31,312 +2439% $2.78* 32,596 17 Aug 2022 Direct F1
transaction CLDX Common Stock Sale $1,150,221 -31,312 -96% $36.73 1,284 17 Aug 2022 Direct F2
transaction CLDX Common Stock Options Exercise $12,217 +1,355 +106% $9.02 2,639 18 Aug 2022 Direct
transaction CLDX Common Stock Sale $49,289 -1,355 -51% $36.38 1,284 18 Aug 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option Options Exercise $0 -31,312 -74% $0.000000 10,750 17 Aug 2022 Common Stock 31,312 $2.78 Direct F4
transaction CLDX Incentive Stock Option Options Exercise $0 -1,355 -12% $0.000000 10,103 18 Aug 2022 Common Stock 1,355 $9.02 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 876 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.54 to $37.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $36.65 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F5 As of June 13, 2022, the option is fully vested.